Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTI 01

Drug Profile

CTI 01

Alternative Names: Ethyl pyruvate; Ethyl pyruvate compound

Latest Information Update: 06 May 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Critical Therapeutics
  • Class Anti-inflammatories; Cytoprotectives
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Shock

Most Recent Events

  • 04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici
  • 19 Sep 2006 Results from a phase II clinical trial have been added to the adverse events and Vascular therapeutic trials sections
  • 22 Mar 2006 Suspended - Phase-II for Shock in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top